Experimental drug aims to treat dangerous blood reaction to common blood thinner
NCT ID NCT05785819
First seen Jan 06, 2026 · Last updated May 26, 2026 · Updated 24 times
Summary
This study tested an experimental drug called VLX-1005 in people with a rare condition called heparin-induced thrombocytopenia (HIT), where a common blood thinner causes low platelets and dangerous blood clots. About 24 adults with suspected HIT received either VLX-1005 or a placebo, along with standard care. The trial was stopped early, so results are limited, but researchers were looking at how quickly platelet levels recovered and whether serious complications like stroke or clots occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA, IMMUNE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carilion Medical Center
Roanoke, Virginia, 24014, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Stanford University
Stanford, California, 94305, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Universiy of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Versiti at Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Yale University
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.